A CNIO‑ and CIEMAT‑led team described an innovative gene‑editing strategy that exploits tumors with high oncogene amplification, using CRISPR‑Cas9 to selectively target cancer cells overloaded with oncogenic copies while sparing normal tissue. The work identifies a vulnerability created by oncogene amplification that can be leveraged therapeutically; the consortium published preclinical data showing selective tumor cell killing via targeted genome disruption. If validated across tumor types and delivery platforms, the approach could open a new avenue for precision oncology against cancers driven by copy‑number amplifications, complementing existing targeted therapies.